Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TERT | O14746 | 1/20 | 0.51 |
| ▸ | PRCP | P42785 | 3/20 | 0.50 |
| ▸ | HTR2C | P28335 | 5/20 | 0.44 |
| ▸ | HTR2B | P41595 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | TLR2 | O60603 | 2/20 | 0.40 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.39 |
| ▸ | CTSC | P53634 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.37 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL464682 | 1.00 | TERT (0.51) | TERTPRCPHTR2CHTR2BKDM4E | |
| SCHEMBL10788824 | 1.00 | TERT (0.51) | TERTPRCPHTR2CHTR2BKDM4E | |
| SCHEMBL30481218 | 1.00 | TERT (0.51) | TERTPRCPHTR2CHTR2BKDM4E | |
| SCHEMBL31142126 | 1.00 | TERT (0.51) | TERTPRCPHTR2CHTR2BKDM4E | |
| SCHEMBL620067 | 0.93 | PRCP (0.55) | TERTPRCPHTR2CHTR2BKDM4E | |
| SCHEMBL620066 | 0.93 | PRCP (0.55) | TERTPRCPHTR2CHTR2BKDM4E | |
| SCHEMBL8789170 | 0.93 | PRCP (0.55) | TERTPRCPHTR2CHTR2BKDM4E | |
| SCHEMBL6372058 | 0.88 | PRCP (0.50) | TERTPRCPHTR2CHTR2BKDM4E | |
| Glycine SCHEMBL2933526 | 0.87 | PRCP (0.50) | TERTPRCPHTR2CHTR2BKDM4E | |
| Trifluoroacetic Acid SCHEMBL19209820 | 0.84 | HTR2C (0.48) | TERTPRCPHTR2CHTR2BKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4017541-A1 | IMMUNE TOLERANT ELASTIN-LIKE RECOMBINANT PEPTIDES AND METHODS OF USE | University of Utah Research Foundation (US) | 2022-06-29 | — | — | EP | claimed |
| EP-0142231-B1 | PROCESS FOR PRODUCING SEQUENTIAL POLYAMINO ACID RESIN | NITTO BOSEKI CO., LTD. (JP) | 1987-11-11 | — | — | EP | claimed |
| EP-0142231-A1 | Process for producing sequential polyamino acid resin | NITTO BOSEKI CO., LTD. (JP) | 1985-05-22 | — | — | EP | claimed |
| US-12622975-B2 | Peptide-conjugated prodrugs | BRANDEIS UNIVERSITY (US) | 2026-05-12 | — | — | US | disclosed |
| US-12415835-B2 | Peptide-compound cyclization method | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-09-16 | — | — | US | disclosed |
| CN-117835996-A9 | Composition for inhibiting biological membrane comprising lactobacillus rhamnosus as active ingredient | VIXXOL有限公司 | 2024-09-03 | — | — | CN | disclosed |
| US-20240216448-A1 | COMPOSITION FOR INHIBITING BIOFILM COMPRISING LACTOBACILLUS RHAMNOSUS AS ACTIVE INGREDIENT | VIXXOL CORPORATION (KR) | 2024-07-04 | — | — | US | disclosed |
| CN-118221777-A | Polypeptide for repairing skin wound or mucous membrane injury and application thereof | 四川好医生攀西药业有限责任公司 | 2024-06-21 | — | — | CN | disclosed |
| CN-114106100-B | Polypeptide for repairing skin wound or mucous membrane injury and application thereof | 四川好医生攀西药业有限责任公司 | 2024-05-17 | — | — | CN | disclosed |
| CN-117835996-A | Composition for inhibiting biological membrane comprising lactobacillus rhamnosus as active ingredient | VIXXOL有限公司 | 2024-04-05 | — | — | CN | disclosed |
| EP-4321166-A1 | COMPOSITION FOR INHIBITING BIOFILM COMPRISING LACTOBACILLUS RHAMNOSUS AS ACTIVE INGREDIENT | Vixxol Corporation (KR) | 2024-02-14 | — | — | EP | disclosed |
| US-11891457-B2 | Peptide-compound cyclization method | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-02-06 | — | — | US | disclosed |
| US-20240024237-A1 | COMPOSITIONS COMPRISING LIPOSOME-ENCAPSULATED THIAZOLIDINEDIONES AND LIPOSOME-ENCAPSULATED VASODILATORS, AND THEIR USE TO AMELIORATE ATHEROMA | UNIV TEXAS (US) | 2024-01-25 | — | — | US | disclosed |
| WO-2023064887-A1 | MECHANOCHEMICAL DYNAMIC THERAPY FOR FOCAL CANCER TREATMENT | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2023-04-20 | — | — | WO | disclosed |
| US-20220387610-A1 | PEPTIDE-CONJUGATED PRODRUGS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-12-08 | — | — | US | disclosed |
| WO-2022215981-A1 | COMPOSITION FOR INHIBITING BIOFILM COMPRISING LACTOBACILLUS RHAMNOSUS AS ACTIVE INGREDIENT | 주식회사 빅솔 | 2022-10-13 | — | — | WO | disclosed |
| EP-4017541-A1 | IMMUNE TOLERANT ELASTIN-LIKE RECOMBINANT PEPTIDES AND METHODS OF USE | University of Utah Research Foundation (US) | 2022-06-29 | — | — | EP | disclosed |
| CN-114478789-A | anti-PD-L1 and OX40 bispecific antibodies and uses thereof | 安徽安科生物工程（集团）股份有限公司 | 2022-05-13 | — | — | CN | disclosed |
| EP-3974563-A1 | CYCLIC PEPTIDES | Chugai Seiyaku Kabushiki Kaisha (JP) | 2022-03-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12622975-B2 | Peptide-conjugated prodrugs | PEPD, PAM, VIP | TERT 4841/4885PRCP 220/4885HTR2C 3536/4885 |
| US-11891457-B2 | Peptide-compound cyclization method | VIP, NGLY1, GLP1R | TERT 2851/4885PRCP 90/4885HTR2C 4722/4885 |
| US-20220387610-A1 | PEPTIDE-CONJUGATED PRODRUGS | VIP, DNPEP, PEPD | TERT 4603/4885PRCP 23/4885HTR2C 4779/4885 |
| US-20240024237-A1 | COMPOSITIONS COMPRISING LIPOSOME-ENCAPSULATED THIAZOLIDINEDIONES AND LIPOSOME-ENCAPSULATED VASODILATORS, AND THEIR USE TO AMELIORATE ATHEROMA | LIPG, LIPA, HDLBP | TERT 2435/4885PRCP 2595/4885HTR2C 2965/4885 |
| US-12415835-B2 | Peptide-compound cyclization method | VIP, NGLY1, GLP1R | TERT 2851/4885PRCP 90/4885HTR2C 4722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.